Reported results with monoclonal antibody therapy in chronic lymphocytic leukemia (CLL).
| Regimen . | Previously Untreated . | Prior Rx . | Dose (4-week schedule) . | %CR + PR . | Ref. . |
|---|---|---|---|---|---|
| Abbreviations: CR, complete response; PR, partial response | |||||
| Rituximab | 43 | — | 375 mg/m2 qw × 4 | 9 + 49 | 46 |
| 6 | 27 | 375 mg/m2 tiw × 4 | 3 + 42 | 40 | |
| — | 50 | 500–2250 mg/m2 qw × 4 | 0 + 36 | 41 | |
| Campath | 0 | 93 | 30 mg tiw × 12 wks IV | 2 + 31 | 42 |
| 38 | — | 30 mg tiw × 18 wks SC | 19 + 68 | 43 | |
| Regimen . | Previously Untreated . | Prior Rx . | Dose (4-week schedule) . | %CR + PR . | Ref. . |
|---|---|---|---|---|---|
| Abbreviations: CR, complete response; PR, partial response | |||||
| Rituximab | 43 | — | 375 mg/m2 qw × 4 | 9 + 49 | 46 |
| 6 | 27 | 375 mg/m2 tiw × 4 | 3 + 42 | 40 | |
| — | 50 | 500–2250 mg/m2 qw × 4 | 0 + 36 | 41 | |
| Campath | 0 | 93 | 30 mg tiw × 12 wks IV | 2 + 31 | 42 |
| 38 | — | 30 mg tiw × 18 wks SC | 19 + 68 | 43 | |